Gilead

4Q Revenues: $2.6 billion (+18%)

4Q Earnings: $759.0 million (+15%)

FY Revenues: $9.7 billion (+16%)

FY Earnings: $2.6 billion (-8%)

Comments: Growth in the quarter was driven by the antiviral franchise. Complera/Eviplera sales were $117.8 million compared to $19.7 million in 4Q11.  Atripla sales were up 6% to $917.5 million and Truvada sales were up 12% to $832.7 million. Sales of Viread were up 19% to $226.7 million. Cardiovascular product sales were up 33% to $215.2 million. Sales of other products, including AmBisome and Cayston, increased 15% to $127.7 million. Royalty, contract and other revenues from collaborations were $77.5 million in the quarter, up 16%.